Where the Money Goes: Why Radiopharma Investment Isn’t Solving the Infrastructure Gap
.png)
Where the Money Goes: Why Radiopharma Investment Isn’t Solving the Infrastructure Gap
Investment in radiopharmaceutical development is increasing.
More therapies are moving into clinical trials, and more resources are being directed toward expanding production. Targeted approaches such as prostate-specific membrane antigen for prostate cancer and somatostatin receptor targeting for neuroendocrine tumors are now well established in oncology pipelines [1].
But there is a growing disconnect.
While scientific progress and investment continue to move forward, the clinical systems required to deliver these therapies are not scaling at the same pace.
Investment Is Focused Upstream
Most activity in radiopharmaceutical development is concentrated in two areas.
The first is drug development. New targeting approaches and radionuclides are expanding the range of treatable cancers. Established pairs such as ⁶⁸Ga-PSMA with ¹⁷⁷Lu-PSMA and ⁶⁸Ga-DOTATATE with ¹⁷⁷Lu-DOTATATE show how imaging and therapy are directly linked in Theragnostic care [1].
The second is manufacturing. Reliable production of isotopes and radioligands is essential, especially because many of these compounds must be used within defined time windows after production.
These investments are necessary. But they do not address the full system required to deliver treatment to patients.
The Clinical Site Gap Remains
Radiopharmaceutical therapies cannot be delivered without prepared clinical sites. Unlike traditional oncology drugs, these therapies require:
- specialized handling and administration
- trained nuclear medicine and imaging staff
- radiation safety processes
- coordination between imaging and therapy teams
Access to nuclear medicine depends on infrastructure, workforce, regulation, and supply working together [2]. This creates a practical limitation.
Even as more therapies become available, the number of sites that can deliver them remains limited.
Why Investment Does Not Reach Clinical Delivery
This gap reflects how development is structured.
Drug development and manufacturing are easier to scale. They align with traditional investment models, where progress is measured through pipeline milestones and production output.
Clinical infrastructure is different. It is:
- tied to individual sites
- dependent on trained staff
- influenced by health system operations
- slower to build and expand
Regulatory guidance also reflects this complexity. Evaluating radiopharmaceutical therapies requires consistent imaging, dosimetry, and safety practices, all of which depend on how well sites can execute protocols [3].
As a result, investment tends to focus upstream, while clinical delivery capacity grows more slowly.
Workforce and Capacity Constraints Are Increasing
Workforce limitations are already affecting the system.
Radiopharmaceutical imaging and therapy rely on specialized teams, including technologists, nuclear medicine physicians, radiopharmacists, and physicists. These roles require specific training and coordination.
Workforce data shows that shortages in imaging professionals are increasing pressure on existing systems and affecting throughput [4].
At the same time, Theragnostic trials are placing greater demands on sites. Protocols often require:
- multiple imaging timepoints
- consistent imaging quality
- coordination across departments
This adds pressure to teams that are already operating near capacity.
The Impact on Development and Access
When clinical infrastructure does not keep pace with development, the effects become clear.
Trials may experience:
- slower patient enrollment
- differences in site performance
- delays in execution
Even when therapies are available and manufacturing is ready, delivery can become the limiting step.
This is not a single issue. It reflects how well the system as a whole is prepared to support radiopharmaceutical development at scale.
The Gap Is Operational, Not Just Financial
Closing this gap requires more than additional funding.
It requires:
- early evaluation of site readiness
- alignment between imaging and treatment workflows
- investment in workforce training
- coordination across clinical teams
The challenge is not just building capacity. It is ensuring that the system can operate effectively in practice.
Theragnostic Insight - Radiopharmaceutical development depends on clinical systems that can deliver imaging and therapy together. Investment that does not account for site readiness and workforce capacity will not fully translate into patient access.
What This Means for Sponsors and Health Systems
For sponsors, clinical infrastructure should be considered early in development planning.
Understanding site capability, staffing, and workflow constraints can improve trial design and reduce delays.
For health systems, the growth of Theragnostic therapies presents an opportunity to build specialized programs.
But this requires investment in people, training, and coordination, not just equipment.
What This Means for You
Radiopharmaceutical development is advancing quickly.
The science is strong. The pipeline is growing.
But the ability to deliver these therapies depends on the systems that support them.
At Theragnostic Insights, we help teams evaluate these dependencies early and align development strategy with real-world clinical execution.
Because in Theragnostic development, success depends not only on innovation, but on the systems that make it possible.
Stay tuned for more in this mini-series: Clinical Capacity Crisis: The Hidden Bottleneck in Radiopharma Development.
In the coming weeks, we’ll continue exploring the clinical capacity crisis holding back radiopharmaceutical innovation, from regional access gaps to operational gridlock and infrastructure blind spots. Don’t miss the next post as we map out the road to a truly trial-capable ecosystem.
- The Trial Site Gap: Why Radiopharmaceutical Innovation Is Hitting a Wall
- Geography Is Destiny: The Clinical Access Gaps in Radiopharmaceutical Research
- Operational Gridlock: Where Radiopharmaceutical Trials Break Down on Site
- Beyond the Badge: Rethinking What “Trial-Ready” Really Means in Radiopharma
- Infrastructure as Investment Strategy: Clinical Site Access and Radiopharma ROI
- Built for What’s Next: Redefining Clinical Site Design for Theragnostic Trials
- Speed as Strategy: How Site Scarcity Is Slowing Radiopharmaceutical Pipelines
- One Roof, Many Bottlenecks: Why Fragmented Site Models Undermine RLT Trials
- The Dosimetry Dilemma: Why Many Sites Aren’t Ready for Radioligand Trials
- Licensing & Radiation Safety: The Regulatory Maze Behind Radiopharmaceutical Trials
- The Hidden Role of Radiation Safety in Clinical Trial Activation
- The Radiopharma Workforce Gap: Who’s Actually Running These Trials?
- The Infrastructure Nobody Funds: Why Clinical Trial Sites Are Missing From Radiopharma Investment
- Manufacturing vs. Clinical Sites: The Missing Investment in Radiopharma Development
- Why Radiopharma Trial Timelines Are Harder to Predict Than Traditional Oncology Trials
- When Imaging Becomes the Bottleneck
- Where the Money Goes: Why Radiopharma Investment Isn’t Solving the Infrastructure Gap
References:
[1] Zhang et al., 2025. Radiopharmaceuticals and their applications in medicine. Signal Transduction and Targeted Therapy
[2] International Atomic Energy Agency, 2024. Nuclear medicine in therapy and diagnosis. IAEA
[3] European Medicines Agency, 2024. Concept paper on the clinical evaluation of therapeutic radiopharmaceuticals in oncology. EMA
[4] American Society of Radiologic Technologists, 2024. Medical imaging workforce shortage white paper. ASRT
https://humanhealth.iaea.org/resources/portfolio/nmdi-nm-in-therapy.html?
